ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · IEX Real-Time Price · USD
1.310
+0.110 (9.17%)
At close: Mar 28, 2024, 4:00 PM
1.280
-0.030 (-2.29%)
After-hours: Mar 28, 2024, 7:59 PM EDT

ABVC BioPharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
0.150.970.360.480.7
Revenue Growth (YoY)
-84.28%172.57%-26.34%-31.16%-
Cost of Revenue
0.30.290.010.020.02
Gross Profit
-0.150.680.350.460.68
Selling, General & Admin
5.376.075.754.273.07
Research & Development
1.062.6910.551.05
Other Operating Expenses
1.647.045.314.150.02
Operating Expenses
8.0715.812.068.974.14
Operating Income
-8.22-15.11-11.71-8.51-3.46
Interest Expense / Income
2.490.290.230.410.48
Other Expense / Income
-0.450.220.081.1-0.22
Pretax Income
-10.26-15.63-12.01-10.01-3.72
Income Tax
0.260.80.83-0.22-0.08
Net Income
-10.52-16.42-12.84-9.79-3.64
Shares Outstanding (Basic)
43322
Shares Outstanding (Diluted)
43322
Shares Change
36.92%26.39%27.07%12.67%-
EPS (Basic)
-2.43-5.19-5.10-5.00-2.10
EPS (Diluted)
-2.43-5.19-5.10-5.00-2.10
Free Cash Flow
-4.26-7.52-7.62-4.56-3.13
Free Cash Flow Per Share
-0.98-2.37-3.04-2.31-1.79
Gross Margin
-98.15%70.47%98.57%96.13%97.13%
Operating Margin
-5390.35%-1558.54%-3290.07%-1760.87%-492.90%
Profit Margin
-6898.68%-1693.50%-3608.47%-2026.97%-518.98%
Free Cash Flow Margin
-2792.79%-775.23%-2140.33%-944.82%-446.69%
EBITDA
-7.74-15.31-11.77-9.57-3.18
EBITDA Margin
-5076.28%-1578.47%-3309.36%-1981.05%-453.42%
Depreciation & Amortization
0.030.020.010.040.06
EBIT
-7.77-15.33-11.79-9.61-3.24
EBIT Margin
-5095.00%-1580.92%-3312.73%-1988.73%-461.27%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).